PTC Therapeutics (PTCT) Given Daily News Sentiment Rating of 0.31
Headlines about PTC Therapeutics (NASDAQ:PTCT) have been trending positive this week, according to Alpha One. Alpha One, a subsidiary of Accern, rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PTC Therapeutics earned a daily sentiment score of 0.31 on Alpha One’s scale. Alpha One also gave headlines about the biopharmaceutical company an impact score of 94 out of 100, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Alpha One Sentiment’s rankings:
- PTC Inc (PTC) Scheduled to Post Earnings on Wednesday (cote-ivoire.com)
- PTC THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) (4-traders.com)
- Quarterly Sales Analysis of PTC Therapeutics, Inc. (NASDAQ:PTCT) – The Newburgh Press (newburghpress.com)
- PTC Therapeutics (PTCT) Receiving Somewhat Critical News Coverage, Report Finds (americanbankingnews.com)
- Time To Get Cautious? – PTC Therapeutics, Inc. (PTCT), Air Methods Corporation (AIRM) – USA Commerce Daily (usacommercedaily.com)
A number of research firms have issued reports on PTCT. Royal Bank of Canada set a $13.00 target price on PTC Therapeutics and gave the company a “hold” rating in a research note on Monday, January 2nd. Cowen and Company reissued a “hold” rating on shares of PTC Therapeutics in a research note on Thursday, March 16th. Credit Suisse Group AG restated a “positive” rating and issued a $25.00 price target on shares of PTC Therapeutics in a report on Monday, March 6th. They noted that the move was a valuation call. Jefferies Group LLC restated a “hold” rating and issued a $12.00 price target on shares of PTC Therapeutics in a report on Tuesday, January 10th. Finally, Barclays PLC lowered PTC Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $20.00 to $13.00 in a report on Friday, March 3rd. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $14.00.
PTC Therapeutics (NASDAQ:PTCT) traded up 3.28% during mid-day trading on Tuesday, reaching $11.03. The company had a trading volume of 1,082,540 shares. The company’s market capitalization is $376.88 million. The stock has a 50 day moving average price of $10.04 and a 200 day moving average price of $11.22. PTC Therapeutics has a one year low of $4.03 and a one year high of $16.50.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.07) by $0.29. PTC Therapeutics had a negative return on equity of 90.33% and a negative net margin of 236.68%. The firm earned $25.20 million during the quarter, compared to the consensus estimate of $24.69 million. During the same period last year, the business posted ($1.50) EPS. The business’s revenue was up 98.4% compared to the same quarter last year. On average, equities analysts expect that PTC Therapeutics will post ($3.70) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “PTC Therapeutics (PTCT) Given Daily News Sentiment Rating of 0.31” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at http://www.dailypolitical.com/2017/04/18/ptc-therapeutics-ptct-given-daily-news-sentiment-rating-of-0-31.html.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.
Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.